Sign In
Buy OTLK
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026
Outlook Therapeutics: August PDUFA For Wet AMD Blockbuster
05:58pm, Friday, 28'th Apr 2023
Oncobiologics, born in pursuit of oncology biosimilars, dramatically shifted its outlook, appropriately rechristening itself as Outlook Pharmaceuticals. Outlook has set its sights full bore on treatme
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
08:05am, Thursday, 27'th Apr 2023
Russ Trenary, President and Chief Executive Officer and Glen Olsheim, Executive Director, Commercial Excellence of Outlook Therapeutics to participate in a live moderated fireside chat on Tuesday, May
Outlook Therapeutics ends 1Q with cash and equivalents of $52.3M; says it has sufficient capital into 4Q 2023
09:42am, Tuesday, 14'th Feb 2023
Outlook Therapeutics Inc (NASDAQ:OTLK) announced that it has ended its first quarter of fiscal 2023 with cash and equivalents of $52.3 million as of December 31, 2022, which the company says is expect
Outlook Therapeutics strengthens medical affairs and commercial expertise with new appointments
09:01am, Thursday, 19'th Jan 2023
Outlook Therapeutics Inc (NASDAQ:OTLK) has announced the appointments of Dr Surendra Sharma as senior vice president of medical affairs and Glen Olsheim as executive director of commercial excellence
Outlook Therapeutics plots course for wet AMD drug approval in year-end shareholder letter
12:06pm, Thursday, 29'th Dec 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) has announced financial results for its fiscal year ended September 30 and laid out plans for 2023 in an end-of-year letter. “Our fiscal year 2022 laid a solid
Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into securities purchase agreements with existing institutional and accredited investors for a registered direct offering priced at-the-marke
Outlook Therapeutics announces validation of marketing authorization application by EMA for ONS-5010 as treatment for wet AMD
09:01am, Thursday, 22'nd Dec 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) announced the validation of the company's Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for an investigational ophthalmic form
Outlook Therapeutics says FDA approval for Lytenava will make huge difference for those with vision loss
07:01am, Friday, 04'th Nov 2022
There's a question the CEO of Outlook Therapeutics Inc (NASDAQ:OTLK) likes to pose about why having US Food and Drug Administration (FDA)-approval will propel the company's upcoming treatment for reti
Outlook Therapeutics encouraged by FDA acceptance of application for drug to treat retinal eye disease wet AMD
09:47am, Friday, 28'th Oct 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) said the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its investigational ophthalmic formulation of bevacizumab
Outlook Therapeutics enters into commercialization agreement with AmerisourceBergen
10:10am, Tuesday, 27'th Sep 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into a strategic relationship with healthcare company AmerisourceBergen in preparation for the anticipated commercial launch in the United St
Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
08:35am, Monday, 26'th Sep 2022
ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic f
Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:05am, Wednesday, 07'th Sep 2022
ISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic f
Outlook Therapeutics re-submits biologics license application for ONS-5010 as a treatment for wet AMD to the FDA
09:49am, Tuesday, 30'th Aug 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) said it has re-submitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) for ONS-5010, an investigational ophthalmic therapy
Outlook Therapeutics strengthens board with appointment of ophthalmologist Dr Julia Haller
09:20am, Monday, 15'th Aug 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc, a pre-commercial biopharmaceutical company working to develop the first US Food and Drug Administration (FDA)-approved ophthalmic formulation of bevacizumab for
Outlook Therapeutics ends 3Q with $26 million in cash and cash equivalents; plans to re-submit ONS-5010 application by September
10:01am, Wednesday, 10'th Aug 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc said it ended the fiscal third quarter with $26 million in cash and cash equivalents that are expected to fund its work into the first calendar quarter of 2023
